TABLE 1.
Characteristics of the patients treated with sitagliptin for 12 weeks
| Whole | Monotherapy | Combination Therapy | ||||
| Pre | Post | Pre | Post | Pre | Post | |
| n (M/F) | 24 (15/9) | 14 (7/7) | 10 (8/2) | |||
| Age (years) | 70.2 ± 2.2 | 72.1 ± 3.1 | 67.5 ± 3.1 | |||
| BMI (kg/m2) | 25.1 ± 1.0 | 25.2 ± 1.0 | 24.7 ± 1.4 | 24.6 ± 1.4 | 25.8 ± 1.6 | 25.9 ± 1.6 |
| Waist circumference (cm) | 88.1 ± 2.3 | 87.0 ± 2.2 | 87.6 ± 3.4 | 85.7 ± 3.2 | 89.0 ± 2.6 | 89.0 ± 2.4 |
| Systolic blood pressure (mmHg) | 140.7 ± 4.0 | 138.6 ± 2.7 | 142.1 ± 5.8 | 137.5 ± 3.6 | 138.8 ± 5.3 | 140.6 ± 3.8 |
| Diastolic blood pressure (mmHg) | 78.7 ± 1.7 | 79.4 ± 2.0 | 79.1 ± 2.7 | 77.3 ± 2.8 | 78.1 ± 1.8 | 83.1 ± 1.9 |
| Pulse rate (beats/min) | 71.1 ± 1.7 | 70.1 ± 1.0 | 72.7 ± 2.5 | 70.9 ± 1.1 | 68.7 ± 1.3 | 67.5 ± 2.1 |
| Biochemical data | ||||||
| Glucose (mg/dl) | 167.5 ± 8.9 | 149.3 ± 6.9a | 170.5 ± 10.4 | 144.1 ± 8.1a | 162.9 ± 16.7 | 156.7 ± 12.2 |
| Insulin (µU/ml) | 9.3 ± 1.8 | 6.8 ± 0.6 | 10.9 ± 2.9 | 6.4 ± 0.9 | 7.1 ± 1.6 | 7.4 ± 0.9 |
| HOMA-R | 4.2 ± 1.0 | 2.5 ± 0.3a | 4.9 ± 1.4 | 2.2 ± 0.4a | 3.1 ± 1.3 | 2.9 ± 0.5 |
| 1,5-AG (µg/ml) | 5.8 ± 1.4 | 9.4 ± 1.6a | 7.3 ± 2.3 | 11.9 ± 2.5a | 3.7 ± 0.7 | 6.2 ± 1.0a |
| HbA1c (%) | 7.7 ± 0.2 | 6.8 ± 0.2a | 7.4 ± 0.2 | 6.6 ± 0.2a | 8.0 ± 0.3 | 7.2 ± 0.3a |
| Total cholesterol (mg/dl) | 193.8 ± 7.2 | 180.0 ± 11.2 | 195.6 ± 11.6 | 185.7 ± 11.2 | 191.6 ± 8.1 | 172.9 ± 21.4 |
| HDL cholesterol (mg/dl) | 46.2 ± 2.2 | 46.3 ± 1.8 | 48.6 ± 3.3 | 47.0 ± 2.0 | 42.8 ± 2.6 | 45.2 ± 3.3 |
| LDL cholesterol (mg/dl) | 115.2 ± 5.7 | 112.8 ± 5.4 | 112.4 ± 8.7 | 106.6 ± 8.2 | 119.7 ± 5.9 | 120.7 ± 6.2 |
| Triglycerides (mg/dl) | 169.6 ± 15.7 | 154.7 ± 13.6 | 172.1 ± 19.6 | 157.6 ± 16.3 | 166.0 ± 27.0 | 150.7 ± 24.2 |
| Cr (mg/dl) | 0.75 ± 0.04 | 0.78 ± 0.03 | 0.76 ± 0.05 | 0.79 ± 0.05 | 0.74 ± 0.05 | 0.76 ± 0.04 |
| eGFR (ml/min/1.73 m2) | 73.6 ± 3.0 | 71.3 ± 14.1 | 70.5 ± 3.7 | 68.0 ± 4.0 | 79.0 ± 4.9 | 76.5 ± 3.8 |
| hsCRP (mg/dl) | 0.28 ± 0.14 | 0.22 ± 0.08 | 0.09 ± 0.03 | 0.07 ± 0.02 | 0.52 ± 0.31 | 0.41 ± 0.18 |
| Diagnosis | ||||||
| Hypertension | 22 (91.7) | 13 (92.9) | 9 (90.0) | |||
| Dyslipidemia | 21 (87.5) | 12 (85.7) | 9 (90.0) | |||
| Medication | ||||||
| Sulfonylurea (glimepiride) | 10 (41.7) | 0 (0) | 10 (100) | |||
| Angiotensin II receptor blocker | 11 (45.8) | 7 (50.0) | 4 (40.0) | |||
| ACE inhibitor | 4 (16.7) | 2 (14.3) | 2 (20.0) | |||
| Direct renin inhibitor | 7 (29.2) | 4 (28.6) | 3 (30.0) | |||
| Calcium channel blocker | 13 (54.2) | 8 (57.1) | 5 (50.0) | |||
| α Blocker | 1 (4.2) | 1 (7.1) | 0 (0) | |||
| β Blocker | 5 (20.8) | 4 (28.6) | 1 (10) | |||
| Diuretics | 1 (4.2) | 1 (7.1) | 0 (0) | |||
| Statin | 10 (41.7) | 7 (50.0) | 3 (30.0) | |||
Variables are expressed as n (%) or means ± SEM.
a
P < 0.05 versus Pre.